TP ICAP analyst raises Esprinet price target, sees over 30% upside

TP ICAP analyst Mathias Paladino maintains a Buy rating on Esprinet and raises the price target, citing potential upside of over 30% despite the stock's appreciation since March. The analyst cites a higher 2026 earnings base from strong Cloud, cybersecurity and AI demand through V-Valley, with Services and Innovexya growth expected from 2027.

Detected & updated continuously · Source: Nebula